KOL Perspectives: Treatment strategies for pregnant RA patients

Questions topics:

› Current views on suitable therapies to treat pregnant RA patients

› Certolizumab –use in pregnant RA patients

› Other anti-TNFs –use in pregnant RA patients

› IL-6 inhibitors –use in pregnant RA patients

› Abatacept –use in pregnant RA patients

› JAK inhibitors –use in pregnant RA patients


› The insight briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs)

› In total, we conducted interviews with 10 KOLs:

– 5 Europe-based & 5 N. America-based

– Interviews performed during Apr 2018

> KOL data is analyzed to produce:

– Charts summarizing KOL opinions

– Chart call-outs of key information & details

– KOL quotes

– Summary of KOL reporting trends

– Insight from Sociable Pharma's analysts

Key Highlights

Majority of KOLs currently use anti-TNFs for treating pregnant RA patients, with a marked preference for certolizumab

No consensus among KOLs on the use of IL-6 inhibitors during pregnancy, although monotherapy use was not considered an advantage

Majority of KOLs were averse to prescribing JAK inhibitors during pregnancy, primarily due to the lack of any data in this setting

Reasons to buy

Combines Qualitative & semi-quantitative insight from key opinion leaders on Treatment strategies for pregnant RA patients

Includes insight & recommendations from our disease-specific healthcare analysts

Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of RA

Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion

Companies mentioned

UCB, AbbVie, Janssen, Roche, Sanofi, Regeneron, BMS

Table of Contents

Table of Contents

Executive Summary


Research Panel Composition

Results & Implications



Discounts available for multiple purchases.

+44 20 7947 2745

Join our mailing list

Saved reports